Why the study?
Does MGN-3 supplementation enhance the apoptotic effect of low-dose paclitaxel in mice bearing Ehrlich ascites carcinoma cells?
Does MGN-3 supplementation enhance the apoptotic effect of low-dose paclitaxel in mice bearing Ehrlich ascites carcinoma cells?
Answers are grounded in this paper and cite their sources.
MGN-3 supplementation enhances tumor cell apoptosis and suppresses tumor growth when combined with a low dose of paclitaxel in a mouse model of Ehrlich ascites carcinoma.
In this study, we examine the ability of arabinoxylan rice bran (MGN-3/Biobran) to enhance the apoptotic effect of paclitaxel (Taxol) at low concentration [2 mg/kg body weight (BW)] in animals bearing Ehrlich ascites carcinoma (EAC) cells and elucidate its mechanisms of action. On Day 8 following tumor cells inoculation, mice bearing tumors were administered MGN-3 alone (40 mg/kg BW), paclitaxel alone, or MGN-3 plus paclitaxel. On Day 30 post-tumor inoculation, we observed significant suppression of tumor volume (TV) with paclitaxel alone (59%), MGN-3 alone (77%), and MGN-3 plus paclitaxel (88%). Inhibition of tumor growth post-treatment with both agents, as compared with either treatment alone, was associated with a decrease in cell proliferation, a marked increase in the sub-G0/G1 population, an increase in DNA damage and apoptosis of tumor cells, and a significant maximization of the apoptosis index (AI)/proliferation index (PrI) ratio. Histopathological and electron microscopy examination of the combined treatment group showed an increase in the degenerative regions of the solid tumor tissue and abundant apoptotic cells. These data suggest that MGN-3 supplementation enhances tumor cell demise in the presence of a low dose of chemotherapeutic agent via apoptotic mechanism.
No takes yet. Share an insight, caveat, or question.
El-Din et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: